Nicole Murphy
Vermögen: 4 Mio $ am 31.05.2026
Vermögen: 4 Mio $ am 31.05.2026
Nicole Murphy currently works at Biogen, Inc. as Head-Pharmaceutical Operations & Technology since 2022.
Former positions include Executive Director & Head-Supply Chain at Amgen, Inc., Head-Technical Operations & Vice President at Bioverativ, Inc., and General Manager & Head-Cambridge Site Operations at Biogen, Inc. from 2015 to 2016.
Education includes graduate and MBA degrees from Rensselaer Polytechnic Institute and an undergraduate degree from the University of Massachusetts.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
BIOGEN INC. 0,01 % | 21.04.2026 | 19 749 ( 0,01 % ) | 4 Mio $ | 31.05.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| BIOGEN INC. | Geschäftsführer | 01.02.2022 |
| Unternehmen | Position | Ende |
|---|---|---|
| BIOGEN INC. | Corporate Officer/Principal | 01.12.2016 |
| AMGEN INC. | Direktor/Vorstandsmitglied | - |
| BIOVERATIV INC | Technik-/Wissenschafts-/F&E-Leiter | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 5 |
|---|---|
Amgen, Inc.
Amgen, Inc. BiotechnologyHealth Technology Discovers, develops, manufactures and delivers human therapeutics | Health Technology |
Biogen, Inc.
Biogen, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets therapies for neurological and neurodegenerative diseases | Health Technology |
Rensselaer Polytechnic Institute
Rensselaer Polytechnic Institute Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Massachusetts
University of Massachusetts Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Bioverativ, Inc.
Bioverativ, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that engages in discovery, research, development and commercialization of therapies for hemophilia & blood disorders | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen